KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -2.59%.

  • Biomarin Pharmaceutical's EBITDA Margin fell 1385.00% to -2.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.91%, marking a year-over-year increase of 174.00%. This contributed to the annual value of 16.97% for FY2024, which is 929.00% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its EBITDA Margin stood at -2.59% for Q3 2025, which was down 112.10% from 21.42% recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EBITDA Margin peaked at 21.60% during Q4 2024, and registered a low of -14.65% during Q4 2021.
  • Its 3-year average for EBITDA Margin is 12.61%, with a median of 11.25% in 2024.
  • Per our database at Business Quant, Biomarin Pharmaceutical's EBITDA Margin slumped by 16,667bps in 2021 and then skyrocketed by 1,738bps in 2024.
  • Biomarin Pharmaceutical's EBITDA Margin (Quarterly) stood at -14.65% in 2021, then spiked by 1,221bps to -2.43% in 2022, then spiked by 666bps to 4.22% in 2023, then surged by 1,738bps to 21.60% in 2024, then tumbled by 1,385bps to -2.59% in 2025.
  • Its EBITDA Margin stands at -2.59% for Q3 2025, versus 21.42% for Q2 2025 and 19.22% for Q1 2025.